240 related articles for article (PubMed ID: 31660078)
1. Lipopolysaccharide-anchored macrophages hijack tumor microtube networks for selective drug transport and augmentation of antitumor effects in orthotopic lung cancer.
Guo L; Zhang Y; Wei R; Wang C; Feng M
Theranostics; 2019; 9(23):6936-6948. PubMed ID: 31660078
[No Abstract] [Full Text] [Related]
2. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
5. Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic Ovarian Carcinoma.
Guo L; Zhang Y; Yang Z; Peng H; Wei R; Wang C; Feng M
ACS Nano; 2019 Feb; 13(2):1078-1096. PubMed ID: 30608136
[TBL] [Abstract][Full Text] [Related]
6. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
7. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
8. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y
BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
12. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
[TBL] [Abstract][Full Text] [Related]
13. Charge-conversional PEG-polypeptide polyionic complex nanoparticles from simple blending of a pair of oppositely charged block copolymers as an intelligent vehicle for efficient antitumor drug delivery.
Lv S; Song W; Tang Z; Li M; Yu H; Hong H; Chen X
Mol Pharm; 2014 May; 11(5):1562-74. PubMed ID: 24606535
[TBL] [Abstract][Full Text] [Related]
14. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Antitumor Efficacy of Macrophage-Mediated Egg Yolk Lipid-Derived Delivery System Against Breast Cancer.
Lv Y; Jun Y; Tang Z; Li X; Tao M; Zhang Z; Liu L; Sun S; Wang Q; Luo C; Zhang L
Int J Nanomedicine; 2020; 15():10075-10084. PubMed ID: 33335395
[TBL] [Abstract][Full Text] [Related]
16. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
17. Milk derived colloid as a novel drug delivery carrier for breast cancer.
Hayashi M; Silanikove N; Chang X; Ravi R; Pham V; Baia G; Paz K; Brait M; Koch WM; Sidransky D
Cancer Biol Ther; 2015; 16(8):1184-93. PubMed ID: 26046946
[TBL] [Abstract][Full Text] [Related]
18. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
19. A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy.
Qiang L; Cai Z; Jiang W; Liu J; Tai Z; Li G; Gong C; Gao S; Gao Y
J Nanobiotechnology; 2019 Jul; 17(1):83. PubMed ID: 31291948
[TBL] [Abstract][Full Text] [Related]
20. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
